EA201170917A1 - Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней - Google Patents

Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней

Info

Publication number
EA201170917A1
EA201170917A1 EA201170917A EA201170917A EA201170917A1 EA 201170917 A1 EA201170917 A1 EA 201170917A1 EA 201170917 A EA201170917 A EA 201170917A EA 201170917 A EA201170917 A EA 201170917A EA 201170917 A1 EA201170917 A1 EA 201170917A1
Authority
EA
Eurasian Patent Office
Prior art keywords
encoded
gene
glucokinase
pharmaceutical compositions
methods
Prior art date
Application number
EA201170917A
Other languages
English (en)
Other versions
EA024878B1 (ru
Inventor
Хайдун Хуан
Original Assignee
Хайдун Хуан
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хайдун Хуан filed Critical Хайдун Хуан
Publication of EA201170917A1 publication Critical patent/EA201170917A1/ru
Publication of EA024878B1 publication Critical patent/EA024878B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Представлен ген, кодирующий мутантную глюкокиназу человека. Ген имеет нуклеотидную последовательность, выбранную из нуклеотидной последовательности, приведенной как SEQ ID NO: 2, и нуклеотидной последовательности, где участок ORF кодирует такую же аминокислотную последовательность, что и кодируемая участком ORF (положение 487-1884) из SEQ ID NO: 2, и остальной участок является таким же, что и участок, не являющийся ORF, из SEQ ID NO: 2. Представлены мутантная глюкокиназа человека, кодируемая геном, рекомбинантные векторы, несущие ген, хозяева, содержащие векторы, их фармацевтические композиции, их применения и способы лечения и предупреждения болезней с их использованием. Мутантная глюкокиназа человека, кодируемая геном, имеет более высокую активность, чем глюкокиназа человека дикого типа, и, таким образом, обеспечивает новый способ контроля глюкозы в крови или предупреждения и лечения нарушения углеводного обмена, в частности, предупреждения и лечения диабета.
EA201170917A 2009-01-07 2010-01-06 Ген, кодирующий мутантную глюкокиназу человека, отличающуюся увеличенной стабильностью, и его применение для контроля глюкозы в крови или предупреждения и лечения нарушений углеводного обмена EA024878B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910000087 2009-01-07
PCT/CN2010/070038 WO2010078842A1 (zh) 2009-01-07 2010-01-06 人葡萄糖激酶突变体编码基因、其编码的酶、重组载体及宿主、其药物组合物、应用以及预防和治疗疾病的方法

Publications (2)

Publication Number Publication Date
EA201170917A1 true EA201170917A1 (ru) 2011-12-30
EA024878B1 EA024878B1 (ru) 2016-10-31

Family

ID=42316263

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170917A EA024878B1 (ru) 2009-01-07 2010-01-06 Ген, кодирующий мутантную глюкокиназу человека, отличающуюся увеличенной стабильностью, и его применение для контроля глюкозы в крови или предупреждения и лечения нарушений углеводного обмена

Country Status (21)

Country Link
US (1) US9029142B2 (ru)
EP (1) EP2388317B1 (ru)
JP (1) JP5721637B2 (ru)
KR (1) KR101300540B1 (ru)
CN (1) CN102272296B (ru)
AP (1) AP3277A (ru)
AU (1) AU2010204379B2 (ru)
BR (1) BRPI1006104B8 (ru)
CA (1) CA2749180C (ru)
DK (1) DK2388317T3 (ru)
EA (1) EA024878B1 (ru)
ES (1) ES2649021T3 (ru)
HU (1) HUE035110T2 (ru)
IL (1) IL213750A (ru)
MA (1) MA33034B1 (ru)
MX (1) MX2011007263A (ru)
NZ (1) NZ593893A (ru)
PT (1) PT2388317T (ru)
SG (1) SG172851A1 (ru)
WO (1) WO2010078842A1 (ru)
ZA (1) ZA201105209B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101383408B1 (ko) 2008-12-29 2014-04-17 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． 세포 유착 방지를 위한 펩티드와 조성물 및 그것의 사용 방법
EP2388317B1 (en) 2009-01-07 2017-08-30 Hangzhou Yiyuan Biotechnology Co. Ltd. A gene encoding a human glucokinase mutant, and uses thereof in the treatment or prevention of disease
WO2013117776A1 (es) * 2012-02-08 2013-08-15 Fundación Pública Andaluza Progreso Y Salud Enzimas glucocinasas con actividad aumentada y su uso en el tratamiento y/o prevención de la diabetes mellitus
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Aseko, Inc. Subcutaneous outpatient management
EP3337402A4 (en) 2015-08-20 2019-04-24 Aseko, Inc. THERAPY ADVISER FOR THE MANAGEMENT OF DIABETES
CN110564777B (zh) * 2019-09-23 2021-09-10 北京希诺谷生物科技有限公司 糖尿病疾病模型犬的建立方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988388A2 (en) * 1997-07-24 2000-03-29 Valentis Inc. Ghrh expression system and methods of use
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
ES2170720B1 (es) * 2000-12-20 2003-12-16 Univ Barcelona Autonoma Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
US20070219346A1 (en) * 2002-04-22 2007-09-20 Mcgill University Glucose sensor and uses thereof
WO2005052132A2 (en) * 2003-11-24 2005-06-09 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
GB0423173D0 (en) * 2004-10-19 2004-11-24 Univ Newcastle Treatment of diabetes
CN101212977A (zh) * 2005-06-01 2008-07-02 国际创新生物技术研究所有限公司 葡萄糖可诱导的胰岛素表达和治疗糖尿病的方法
DK2185696T3 (en) * 2007-08-10 2015-10-26 Univ Sydney Tech Cells genetically modified to include pancreatic glucokinase, and uses thereof
EP2388317B1 (en) 2009-01-07 2017-08-30 Hangzhou Yiyuan Biotechnology Co. Ltd. A gene encoding a human glucokinase mutant, and uses thereof in the treatment or prevention of disease

Also Published As

Publication number Publication date
JP5721637B2 (ja) 2015-05-20
ZA201105209B (en) 2012-09-26
MX2011007263A (es) 2011-10-06
EP2388317A4 (en) 2012-11-28
AU2010204379B2 (en) 2014-02-13
CA2749180A1 (en) 2010-07-15
WO2010078842A1 (zh) 2010-07-15
BRPI1006104B1 (pt) 2021-04-20
EA024878B1 (ru) 2016-10-31
CN102272296A (zh) 2011-12-07
SG172851A1 (en) 2011-08-29
MA33034B1 (fr) 2012-02-01
KR20110099057A (ko) 2011-09-05
IL213750A (en) 2015-11-30
US9029142B2 (en) 2015-05-12
AP3277A (en) 2015-05-31
KR101300540B1 (ko) 2013-09-02
BRPI1006104B8 (pt) 2021-05-25
EP2388317B1 (en) 2017-08-30
JP2012514463A (ja) 2012-06-28
IL213750A0 (en) 2011-07-31
DK2388317T3 (da) 2017-11-27
ES2649021T3 (es) 2018-01-09
PT2388317T (pt) 2017-11-27
AP2011005814A0 (en) 2011-08-31
BRPI1006104A2 (pt) 2016-02-16
HUE035110T2 (en) 2018-05-02
US20110286984A1 (en) 2011-11-24
CN102272296B (zh) 2012-10-24
CA2749180C (en) 2017-03-21
EP2388317A1 (en) 2011-11-23
NZ593893A (en) 2013-02-22
AU2010204379A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
EA201170917A1 (ru) Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней
JP5840623B2 (ja) 気道のウイルス感染症の治療に用いるｅｖ５７６
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
NZ717030A (en) Growth differentiation factor 15 (gdf-15) constructs
JP2005533481A5 (ru)
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
EP2910632B1 (en) Highly functional enzyme having modified substrate specificity of human beta-hexosaminidase b and exhibiting protease resistance
RU2014134365A (ru) Вакцины против clostridium difficile, включающие рекомбинантные токсины
JP2014513952A5 (ru)
SG170819A1 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
TW202400634A (zh) 一種用於癌症、肥胖、代謝失調、及相關併發症與合併症之精胺酸消耗劑的組成物及用途
IL201963A (en) Vectors for multi-gene expression, host cell and pharmacy preparation containing and using them
NZ597601A (en) Treatment and prevention of influenza
CA2863578C (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
JP2009507474A5 (ru)
AU2012366182A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein A-IV
JP2017529326A5 (ru)
EP2114431A4 (en) ARAZYME-CONTAINING COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER
ZA202210127B (en) Codon optimized gla genes and uses thereof
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
WO2009058970A3 (en) A novel gene therapy approach for treating the metabolic disorder obesity
EP1813289A4 (en) MEDICINAL COMPOSITION FOR THE TREATMENT OF CANCER OR DIABETES
UA93658C2 (en) Cell surface glycoprotein
EA200801807A1 (ru) Новые оксидоредуктазы и их применение
WO2009044294A3 (en) Means and methods for the treatment of cataract and presbyopia

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment